Radical prostatectomy can provide superior survival compared with radiation therapy, especially in young and healthy men.
Personally tailored intervention generates patient interest, QoL improvements.
Benefit evident regardless of metastasis site, phase III analysis shows.
~40% of sipuleucel-T recipients in lowest PSA quartile alive after 5 years.
It appears to be safe for clinicians to consider testosterone therapy for symptomatic men with testosterone deficiency and a history of prostate cancer, according to new data presented at the AUA annual meeting in San Francisco.
Although active surveillance for prostate cancer is on the rise in younger, privately insured men, many patients do not undergo a repeat biopsy.
The combination appears to be a more powerful predictor than mpMRI/PSA density.
Other take-home messages on transplantation from AUA 2018 included the finding that kidney paired donations have more than doubled since their inception in 2009 as well as early robotic kidney transplantation studies.
"Despite the potential benefits (fewer biopsies, less cost), the proposed approach to cancer detection and biopsy—that can miss 16%-40% of existing csPCa—may be difficult to justify for all patients," writes Badar M. Mian, MD.
Other key prostate cancer studies from AUA 2018 included updated survival data from the European Randomized Study of Screening for Prostate Cancer and a multicenter trial of MRI-targeted biopsy.